[go: up one dir, main page]

AR046886A1 - Analogos de rifamicina y usos de los mismos. - Google Patents

Analogos de rifamicina y usos de los mismos.

Info

Publication number
AR046886A1
AR046886A1 ARP040104623A ARP040104623A AR046886A1 AR 046886 A1 AR046886 A1 AR 046886A1 AR P040104623 A ARP040104623 A AR P040104623A AR P040104623 A ARP040104623 A AR P040104623A AR 046886 A1 AR046886 A1 AR 046886A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkaryl
heteroaryl
aryl
alkylheteroaryl
Prior art date
Application number
ARP040104623A
Other languages
English (en)
Original Assignee
Activbiotics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Activbiotics Inc filed Critical Activbiotics Inc
Publication of AR046886A1 publication Critical patent/AR046886A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El presente se refiere a composición farmacéutica que los contiene y usos. Reivindicación 1: Un compuesto que tiene la fórmula (1), o una de sus sales farmacéuticamente aceptables, en donde: a) A es H, OH, O-(alquilo C1-6), O-(alcarilo C1-4), O- (arilo C6-12), O-(heteroarilo C1-9), u O-(alqheteroarilo C1-4); W es O, S o NR1, en donde R1 es H, alquilo C1-6, alcarilo C1-4 o alqheteroarilo C1-4; X es H o COR2, en donde R2 es alquilo C1-6, que puede estar sustituido con 1-5 grupos OH, O- (alquilo C3-7), que puede estar sustituido con 1-4 grupos OH, arilo C6-12, alcarilo C1-4, heteroarilo C1-9, o alqheteroarilo C1-4, en donde cada carbono del alquilo está unido a no más de un átomo de oxígeno; Y es H, Hal, u OR3, en donde R3 es alquilo C1-6, arilo C6-12, alcarilo C1-4, heteroarilo C1-9 o alqheteroarilo C1-4; R4 es OR5, SR5 o NR5R6, en donde R5 se define más abajo en relación con R7 y R6 es H, alquilo C1-6, arilo C6-12, alcarilo C1-4, heteroarilo C1-9 o alqheteroarilo C1-4, COR9, CO2R9, CONHR9, CSR9, COSR9, CSOR9, CSNHR9, SO2R9 o SO2NHR9, en donde R9 es alquilo C1-6, arilo C6-12, alcarilo C1-4, heteroarilo o alqheteroarilo C1-4; y Z es (CR11R12)nNR7R8, en donde n es 0 ó 1, R7 y R5 representan juntos un enlace o forman un enlace C1-4 sustituido o insustituido, R8 es H, alquilo C1-6, arilo C6-12, alcarilo C1-4, heteroarilo C1-9 o alqheteroarilo C1-4, COR10, CO2R10, CONHR10, CSR10, COSR10, CSOR10, CSNHR10, SO2R10 o SO2NHR10, en donde R10 es alquilo C1-6, arilo C6- 12, alcarilo C1-4, heteroarilo C1-9 o alqheteroarilo C1-4 o R8 no existe y se forma un enlace doble entre N y un enlace de carbono C1 R5-R7, cada uno de R11 y R12 es, de modo independiente, H, alquilo C1-6, alcarilo C1-4 o alqheteroarilo C1-4 o R12 no existe y se forma un enlace doble entre N y el carbono que lleva R11; o b) A es H, OH, O-(alquilo C1-6), O-(alcarilo C1-4), O-(arilo C6-12), O-(heteroarilo C1-9), u O-(alqheteroarilo C1-4); W es O, S o NR1, en donde R1 es H, alquilo C1-6, alcarilo C1-4 o alqheteroarilo C1-4; X es H o COR2, en donde R2 es alquilo C1-6, que puede estar sustituido con 1-5 grupos OH, O-(alquilo C3-7), que puede estar sustituido con 1-4 grupos OH, arilo C6-12, alcarilo C1-4, heteroarilo C1-9, o alqheteroarilo C1-4, en donde cada carbono del alquilo está unido a no más de un átomo de oxígeno; Z es H, Hal, u OR3, en donde R3 es alquilo C1-6, arilo C6-12, alcarilo C1-4, heteroarilo C1-9 o alqheteroarilo C1-4; R4 es OR5, SR5 o NR5R6, en donde R5 se define más abajo en relación con R7 y R6 es H, alquilo C1-6, arilo C6-12, alcarilo C1-4, heteroarilo C1-9 o alqheteroarilo C1-4, COR9, CO2R9, CONHR9, CSR9, COSR9, CSOR9, CSNHR9, SO2R9 o SO2NHR9, en donde R9 es alquilo C1-6, arilo C6-12, alcarilo C1-4, heteroarilo o alqheteroarilo C1-4; y Y es (CR11R12)nNR7R8, en donde n es 0 ó 1, R7 y R5 representan juntos un enlace o forman un enlace C1-4 sustituido o insustituido, R8 es H, alquilo C1-6, arilo C6-12, alcarilo C1-4, heteroarilo C1- 9 o alqheteroarilo C1-4, COR10, CO2R10, CONHR10, CSR10, COSR10, CSOR10, CSNHR10, SO2R10 o SO2NHR10, en donde R10 es alquilo C1-6, arilo C6-12, alcarilo C1-4, heteroarilo C1-9 o alqheteroarilo C1-4 o R8 no existe y se forma un enlace doble entre N y un enlace de carbono C1 R5-R7, cada uno de R11 y R12 es, de modo independiente, H, alquilo C1-6, alcarilo C1-4 o alqheteroarilo C1-4 o R12 no existe y se forma un enlace doble entre N y el carbono que lleva R11.
ARP040104623A 2003-12-10 2004-12-10 Analogos de rifamicina y usos de los mismos. AR046886A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52873303P 2003-12-10 2003-12-10

Publications (1)

Publication Number Publication Date
AR046886A1 true AR046886A1 (es) 2005-12-28

Family

ID=34699896

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104623A AR046886A1 (es) 2003-12-10 2004-12-10 Analogos de rifamicina y usos de los mismos.

Country Status (9)

Country Link
US (2) US7220738B2 (es)
EP (1) EP1697382A4 (es)
JP (1) JP2007513961A (es)
KR (1) KR20070015506A (es)
AR (1) AR046886A1 (es)
AU (1) AU2004298983A1 (es)
CA (1) CA2549001A1 (es)
TW (1) TW200529856A (es)
WO (1) WO2005058231A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200418485A (en) * 2002-09-23 2004-10-01 Activbiotics Inc Rifalazil compositions and therapeutic regimens
JP2007503439A (ja) 2003-08-22 2007-02-22 アクティブバイオティクス インコーポレイティッド リファマイシンアナログおよびそれらの使用法
JP2007516291A (ja) 2003-12-23 2007-06-21 アクティブバイオティクス インコーポレイティッド リファマイシンアナログおよびその使用法
KR101313395B1 (ko) 2005-09-12 2013-10-02 액테리온 파마슈티칼 리미티드 피리미딘-설파마이드를 함유하는 안정한 제약학적 조성물
US7547692B2 (en) * 2005-12-14 2009-06-16 Activbiotics Pharma, Llc Rifamycin analogs and uses thereof
EP2012877B1 (en) * 2006-04-28 2012-08-29 Ondine International Holdings Ltd. Photodisinfection delivery devices
WO2009064792A1 (en) * 2007-11-16 2009-05-22 Cumbre Pharmaceuticals Inc. Quinolone carboxylic acid-substituted rifamycin derivatives
US8822410B2 (en) * 2008-05-19 2014-09-02 Children's Medical Center Corporation Tympanic membrane permeating ear drops and uses thereof
WO2009149149A1 (en) * 2008-06-04 2009-12-10 Trustees Of Dartmouth College Prevention or treatment of immune-relevant disease by modification of microfloral populations
CN102215689A (zh) * 2008-09-17 2011-10-12 鞘氨醇单胞菌研究合作伙伴有限合伙公司 白血病和特发性再生障碍性贫血的治疗
US20100311686A1 (en) * 2009-06-03 2010-12-09 Kasper Lloyd H Nutraceutical composition and methods for preventing or treating multiple sclerosis
US8580278B2 (en) 2009-06-03 2013-11-12 Trustees Of Dartmouth College Nutraceutical composition and methods for preventing or treating multiple sclerosis
WO2013009945A1 (en) 2011-07-12 2013-01-17 The Brigham And Women's Hospital, Inc. Lipid-containing psa compositions, methods of isolation and methods of use thereof
US20140377373A1 (en) * 2011-11-10 2014-12-25 Lankenau Institute For Medical Research Compositions and Methods for the Prevention of Microbial Infections
KR102826997B1 (ko) 2015-08-05 2025-07-01 칠드런'즈 메디컬 센터 코포레이션 약물 전달을 위한 침투 증강제를 수반한 조성물
CN113637040A (zh) 2015-08-19 2021-11-12 哈佛学院院长及董事 脂化psa组合物和方法
WO2018014012A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
CN110467629B (zh) * 2018-05-09 2022-04-08 上海迪诺医药科技有限公司 苯醌衍生物、其药物组合物及应用
WO2025157240A1 (zh) * 2024-01-26 2025-07-31 丹诺医药（苏州）股份有限公司 化合物用于制备治疗细菌代谢相关疾病的药物的用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL130099C (es) * 1963-10-11
JPS58225093A (ja) 1982-06-25 1983-12-27 Kanegafuchi Chem Ind Co Ltd ベンゾチアジノリフアマイシン誘導体およびその製造法
JPS59231092A (ja) 1983-06-11 1984-12-25 Kanebo Ltd フエノチアジン型リフアマイシンおよびその医薬用途
US4690919A (en) * 1984-01-04 1987-09-01 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Benzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same
JPS6122090A (ja) 1984-07-09 1986-01-30 Kanebo Ltd アミノ置換フエノチアジン型リフアマイシンおよびその医薬用途
JPS62240688A (ja) 1986-04-12 1987-10-21 Kanegafuchi Chem Ind Co Ltd ヒドロキシメチル基を有するアミノベンゾキサジノおよびアミノベンゾチアジノリフアマイシン誘導体
JPS62242687A (ja) 1986-04-15 1987-10-23 Kanegafuchi Chem Ind Co Ltd 置換ベンゾキサジノおよび置換ベンゾチアジノリフアマイシン誘導体
JP2544375B2 (ja) * 1986-07-14 1996-10-16 鐘淵化学工業株式会社 アルキル置換ベンゾキサジノリフアマイシン誘導体
JPS6335579A (ja) 1986-07-31 1988-02-16 Kanegafuchi Chem Ind Co Ltd 含硫ベンゾキサジノリフアマイシン誘導体
JPS6335578A (ja) * 1986-07-31 1988-02-16 Kanegafuchi Chem Ind Co Ltd ベンゾキサジノまたはベンゾチアジノリフアマイシン誘導体
JPS63233987A (ja) 1987-03-23 1988-09-29 Kanegafuchi Chem Ind Co Ltd ４′−ｔｅｒｔ−ブチルベンゾキサジノリフアマイシン誘導体
ES2088870T3 (es) * 1988-03-18 1996-10-01 Kanegafuchi Chemical Ind Un derivado de benzoxazinorrifamicina sustituida, un procedimiento para preparar el mismo y un agente antibacteriano que contiene el mismo.
CA1304363C (en) * 1988-11-01 1992-06-30 Takehiko Yamane 3'-hydroxybenzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same
ES2124794T3 (es) * 1992-10-09 1999-02-16 Kanegafuchi Chemical Ind Procedimiento para producir granulados finos.
US5981522A (en) 1995-09-01 1999-11-09 Kaneka Corporation Treatment of disease caused by infection of Helicobacter
EP0787494B1 (en) 1995-09-01 2004-06-09 Kaneka Corporation Use of rifamycin derivatives for the manufacture of a medicament for the treatment of diseases caused by infections of helicobacter pylori
JP3963976B2 (ja) * 1995-12-08 2007-08-22 株式会社カネカ クラミジア感染症治療剤
JPH10258509A (ja) * 1997-03-19 1998-09-29 Fujitsu Ltd インクジェットヘッド及びその製造方法
US6486161B1 (en) * 1998-07-29 2002-11-26 Kaneka Corporation Use of rifamycin derivative for treating mastitis in a domestic animal
US6316433B1 (en) * 1998-12-18 2001-11-13 Kaneka Corporation Method for treatment of bacterial infections with once or twice-weekly administered rifalazil
AU2002368203A1 (en) * 2001-09-06 2004-05-04 Activbiotics, Inc. Antimicrobial agents and uses thereof
US7122525B2 (en) * 2001-11-21 2006-10-17 Activbiotics, Inc. Targeted therapeutics and uses thereof
WO2003051300A2 (en) * 2001-12-13 2003-06-26 Activbiotics, Inc. Metal complexes and formulations of rifamycin analogues and uses therof
AU2002364162A1 (en) * 2001-12-13 2003-06-30 Activbiotics, Inc. Sulfhydryl rifamycins and uses thereof
EP1531828A4 (en) * 2002-05-23 2005-11-02 Activbiotics Inc METHODS OF TREATING BACTERIAL INFECTIONS AND ASSOCIATED DISEASES
US20040077533A1 (en) * 2002-05-23 2004-04-22 Sayada Chalom B. Methods and compositions for treating bacterial infections and diseases associated therewith
WO2003101445A1 (en) * 2002-06-03 2003-12-11 Activbiotics, Inc. Intravenous rifalazil formulation and methods of use thereof
TW200500071A (en) * 2002-08-29 2005-01-01 Activbiotics Inc Methods and reagents for treating infections of clostridium difficile and diseases associated therewith
JP2007503439A (ja) 2003-08-22 2007-02-22 アクティブバイオティクス インコーポレイティッド リファマイシンアナログおよびそれらの使用法
JP2007516291A (ja) 2003-12-23 2007-06-21 アクティブバイオティクス インコーポレイティッド リファマイシンアナログおよびその使用法

Also Published As

Publication number Publication date
US7220738B2 (en) 2007-05-22
EP1697382A2 (en) 2006-09-06
WO2005058231A2 (en) 2005-06-30
US7494991B2 (en) 2009-02-24
AU2004298983A1 (en) 2005-06-30
WO2005058231A3 (en) 2005-12-22
EP1697382A4 (en) 2008-11-05
US20050137189A1 (en) 2005-06-23
CA2549001A1 (en) 2005-06-30
JP2007513961A (ja) 2007-05-31
KR20070015506A (ko) 2007-02-05
TW200529856A (en) 2005-09-16
US20070238747A1 (en) 2007-10-11

Similar Documents

Publication Publication Date Title
AR046886A1 (es) Analogos de rifamicina y usos de los mismos.
HUP0302825A2 (hu) Lipidben gazdag plakkok csökkentésére szolgáló szerek
AR046200A1 (es) Derivados de pirazina y su uso farmaceutico. procesos de preparacion y composiciones farmaceuticas
CO6290657A2 (es) Derivados polisustituidos de 2-aril-6-fenil-imidazo[1,2-alfa]piridinas su preparacion y su aplicacion en terapeutica
CO5550472A2 (es) Piperazinas heterociclicas sustituidas para el tratamiento de la esquizofrenia
AR061181A1 (es) Compuestos de aziridinil-epotilona
ES2667477T3 (es) Compuestos heterobiciclo-sustituidos-[1,2,4]triazolo[1,5-c]quinazolin-5-amina adecuados para el tratamiento o la prevención de trastornos del sistema nervioso central
AR064730A1 (es) Derivados de 2,4-dianilinopirimidinas, su preparacion, composiciones farmaceuticas y usos como inhibidores de ikk
AR048567A1 (es) Derivados de benzoxazinona, su preparacion y composiciones farmaceuticas.
CO5690596A2 (es) Derivados de hexahidropirazino [1,2-a]pirimidin-4,7-diona sustituidos, en el nitrogeno, metodo para su produccion y su uso como medicamentos
NI200900037A (es) Derivados de 2-aril-6-fenil-imidazo[1,2-alfa] piridinas, su preparación y su aplicación en terapéutica.
AR061739A1 (es) Nuevos derivados naftalenicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR065795A1 (es) Derivados de aza-piridopirimidinona,metodo de preparacion,medicamentos que los contienen y usos como agentes antitromboticos, antihiperlipidemicos y antidiabeticos,entre otros.
AR064517A1 (es) Pirimidinionas biciclicas y sus usos
AR049543A1 (es) Derivados de la 1-amino-ftalazina, su preparacion y su aplicacion en terapeutica
CO5031250A1 (es) Compuesto farmaceutico
AR061835A1 (es) Derivados tetraciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR070733A1 (es) Derivados de platino-carbeno n-heterociclico, su preparacion, su composicion farmaceutica y su uso para el tratamiento del cancer
GT200700084A (es) Derivados de indanil-piperazinas, su procedimiento de preparación y las composiciones farmaceuticas que los contienen.
AR041883A1 (es) Compuestos de piridopirimidinona, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
CO4790152A1 (es) Derivados de pirrolopirrolona
AR061377A1 (es) Derivados diazeniodiolatos, procedimiento de preparacion, composiciones farmaceuticas que los contienen y usos en patologias cardiovasculares.
PE20050336A1 (es) Compuestos triciclicos como inhibidores de la proteina farnesil transferasa
AR039557A1 (es) Inhibidores novedosos de la farnesil proteina transferasa como agentes antitumorales
CY1115368T1 (el) Παραγωγα της 2-πυριδιν-2-υλο-πυραζολ-3(2η)-ονης, η παρασκευη τους και η εφαρμογη τους στη θεραπευτικη ως ενεργοποιητες του ηιf

Legal Events

Date Code Title Description
FB Suspension of granting procedure